CODX vs RCL · rev $3.9M vs P/E 26, rev $16.48B
Co-Diagnostics, Inc. Common Stock (CODX) versus Royal Caribbean Cruises Ltd (RCL) — a side-by-side from cached financials, not a winner call.
Co-Diagnostics, Inc. Common Stock (CODX) is a medical devices company listed on US.
Royal Caribbean Cruises Ltd (RCL) is a travel services company listed on US.
Latest reported CODX revenue for 2024-12-31 was $3.9M. Net income was -$37.6M. Revenue was down 42.5% from 2023-12-31 to 2024-12-31. CODX currently screens at market cap $31.4M.
Latest reported RCL revenue for 2024-12-31 was $16.48B. Net income was $2.90B. Revenue was up 18.6% from 2023-12-31 to 2024-12-31. RCL currently screens at market cap $85.57B and trailing P/E 25.7.
CODX currently screens at market cap $31.4M. RCL currently screens at market cap $85.57B and trailing P/E 25.7.
Not investment advice. Open the CODX and RCL stock pages for the full models.
Not investment advice.